Digital Health Innovators – Brian Quigley and Mario Danek (Live from... At HLTH last month, pharmaphorum Editor in Chief Jonah Comstock sat down with the CEO and CTO respectively of QNovia, Brian Quigley and Mario Danek.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.